Back to Search
Start Over
Trial of pancreatic cancer did not meet primary endpoint
- Source :
- Health & Medicine Week. March 14, 2005, 1247
- Publication Year :
- 2005
-
Abstract
- Aphton Corporation (APHT) announced that its phase III study of Insegia (G17DT immunogen) in combination with chemotherapy did not meet its primary efficacy endpoint of improving overall survival in patients [...]
- Subjects :
- Aphton Corp. -- Product development
Eli Lilly and Co. -- Product development
Health aspects
Product development
Clinical trials -- Health aspects
Gastrin -- Health aspects
Pancreatic cancer -- Health aspects
Chemotherapy -- Health aspects
Medical research -- Health aspects
Pharmaceutical industry -- Health aspects -- Product development
Peptide hormones -- Health aspects
Cancer metastasis -- Health aspects
Medicine, Experimental -- Health aspects
Metastasis -- Health aspects
Cancer -- Chemotherapy
Subjects
Details
- Language :
- English
- ISSN :
- 15316459
- Database :
- Gale General OneFile
- Journal :
- Health & Medicine Week
- Publication Type :
- News
- Accession number :
- edsgcl.212922718